



RECEIVED

MAR 1 2002

TECH CENTER 1600/2900

PTO/SB/21 (08-00)

Please place plus sign (+) inside this box → ☐

Approved for use through 10/31/02. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**TRANSMITTAL
FORM**

(to be used for all correspondence after initial filing)

Total Number Of Pages In This Submission

10 + 32
Refs.

Application Number

09/993,045

Filing Date

November 13, 2001

First Named Inventor

Timothy R. BRAZELTON

Group Art Unit

1614

Examiner Name

To Be Assigned

Attorney Docket No.

286002021300

ENCLOSURES (check all that apply)

- | | | |
|--|--|---|
| <input type="checkbox"/> Fee Transmittal Form | <input type="checkbox"/> Assignment Papers
(for an Application) | <input type="checkbox"/> After Allowance Communication to Group |
| <input type="checkbox"/> Fee Attached | <input type="checkbox"/> Drawing(s) | <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences |
| <input type="checkbox"/> Amendment / Reply | <input type="checkbox"/> Licensing-related Papers | <input type="checkbox"/> Appeal Communication to Group
(Appeal Notice, Brief, Reply Brief) |
| <input type="checkbox"/> After Final | <input type="checkbox"/> Petition | <input type="checkbox"/> Proprietary Information |
| <input type="checkbox"/> Affidavits/declarations | <input type="checkbox"/> Petition to Convert to a Provisional Application | <input type="checkbox"/> Status Letter |
| <input type="checkbox"/> Extension of Time Request | <input type="checkbox"/> Power of Attorney, Revocation
Change of Correspondence Address | <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below):
Form PTO-1449 (3 pages in duplicate)
32 cited references
Return receipt postcard |
| <input type="checkbox"/> Express Abandonment Request | <input type="checkbox"/> Terminal Disclaimer | |
| <input checked="" type="checkbox"/> Information Disclosure Statement (3 pages) | <input type="checkbox"/> Request for Refund | |
| <input type="checkbox"/> Certified Copy of Priority Document(s) | <input type="checkbox"/> CD, Number of CD(s) _____ | |

- | | |
|---|---------|
| <input type="checkbox"/> Response to Missing Parts/
Incomplete Application | Remarks |
| <input type="checkbox"/> Response to Missing Parts
under 37 CFR 1.52 or 1.53 | |

SIGNATURE OF APPLICANT, ATTORNEY OR AGENT

Firm or Individual Name	Morrison & Foerster LLP, 755 Page Mill Road, Palo Alto, CA 94304-1018
Signature	
Date	March 4, 2002

CERTIFICATE OF MAILING BY "FIRST CLASS MAIL"

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231, on March 4, 2002.

Martina Placid

Burden Hours Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Box Patent Application, Washington, DC 20231.



RECEIVED

PATENT
Docket No. 286002021300
MAR 12 2002

CERTIFICATE OF MAILING BY "FIRST CLASS MAIL"

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:
Assistant Commissioner for Patents, Washington, D.C. 20231, on March 4, 2002.

Martina Placid
Martina Placid

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the application of:

Timothy R. BRAZELTON and Helen M.
BLAU

Serial No.: 09/993,045

Filing Date: November 13, 2001

For: METHODS FOR TREATING
DISORDERS OF NEURONAL
DEFICIENCY WITH BONE MARROW-
DERIVED CELLS

Examiner: To Be Assigned

Group Art Unit: 1614

INFORMATION DISCLOSURE
STATEMENT UNDER 37 C.F.R. § 1.97

Assistant Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

Pursuant to 37 C.F.R. § 1.97 and § 1.98, Applicants submit for consideration in the above-identified application the documents listed on the attached Form PTO-1449. Copies of the documents are also submitted herewith. The Examiner is requested to make these documents of record.

This Information Disclosure Statement is submitted:

- ☐ With the application; accordingly, no fee or separate requirements are required.
- ☒ Within three months of the application filing date or before mailing of a first Office Action on the merits; accordingly, no fee or separate requirements are required.
- ☐ After receipt of a first Office Action on the merits but before mailing of a final Office Action or Notice of Allowance.
 - ☐ A fee is required. A check in the amount of * is enclosed.
 - ☐ A fee is required. Accordingly, a Fee Transmittal form (PTO/SB/17) is attached to this submission in duplicate.
 - ☐ A Certification under 37 C.F.R. § 1.97(e) is provided below; accordingly, no fee is believed to be due.
- ☐ After mailing of a final Office Action or Notice of Allowance, but before payment of the issue fee.
 - ☐ A Certification under 37 C.F.R. § 1.97(e) is provided below and a check in the amount of * is enclosed.
 - ☐ A Certification under 37 C.F.R. § 1.97(e) is provided below and a Fee Transmittal form (PTO/SB/17) is attached to this submission in duplicate.

Applicants would appreciate the Examiner initialing and returning the Form PTO-1449, indicating that the information has been considered and made of record herein.


The information contained in this Information Disclosure Statement under 37 C.F.R. § 1.97 is not to be construed as a representation that: (i) a complete search has been made; (ii) additional information material to the examination of this application does not exist; (iii) the information, protocols, results and the like reported by third parties are accurate or enabling; or (iv) the above information constitutes prior art to the subject invention.

In the unlikely event that the transmittal letter is separated from this document and the Patent Office determines that an extension and/or other relief is required, Applicants petition for any required relief including extensions of time and authorizes the Assistant Commissioner to

charge the cost of such petitions and/or other fees due in connection with the filing of this document to **Deposit Account No. 03-1952** referencing 286002021300. However, the Assistant Commissioner is not authorized to charge the cost of the issue fee to the Deposit Account.

Dated: March 4, 2002

Respectfully submitted,

By: 
Shantanu Basu
Registration No. 43,318

Morrison & Foerster LLP
755 Page Mill Road
Palo Alto, California 94304-1018
Telephone: (650) 813-5995
Facsimile: (650) 494-0792

Form PTO-1449

INFORMATION DISCLOSURE CITATION
IN AN APPLICATION

(Use several sheets if necessary)

Docket Number 286002021300

Application Number 09/003,045


Applicant

Timothy R. BRAZELTON and Helen M. BLAU

Filing Date November 13, 2001

Group Art Unit 1614

Mailing Date March 4, 2002

RECEIVED
MAR 15 2002
TECH CENTER 1600/2900

RECEIVED

U.S. PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass	Filing Date If Appropriate
	1.	02/16/1993	5,187,193	Borch et al.			
	2.	07/30/1996	5,541,107	Naughton et al.			
	3.	12/01/1998	5,843,438	Papayannopoulou			
	4.	07/20/1999	5,925,568	Comer et al.			

FOREIGN PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Country	Class	Subclass	Translation YES NO

OTHER DOCUMENTS


(including author, title, Date, Pertinent Pages, Etc.)

Examiner Initials	Ref. No.	Title
	5.	Ambler, M.W. et al. (1983). "Infantile osteopetrosis and neuronal storage disease," <i>Neurology</i> 33(4):437-441.
	6.	Anderlini, P. and Körbling, M. (1997). "The use of mobilized peripheral blood stem cells from normal donors for allografting," <i>Stem Cells</i> 15:9-17.
	7.	Ausubel, F.M. et al. eds., (1987). <i>Current Protocols in Molecular Biology</i> , John Wiley and Sons, Inc.: New York, pp.1-11 (Table of Contents).
	8.	Baker, G.A. et al. (1991). "The development of a seizure severity scale as an outcome measure in epilepsy," <i>Epilepsy Res.</i> 8(3):245-251.
	9.	Brazelton, T.R. et al. (2000). "From marrow to brain: expression of neuronal phenotypes in adult mice," <i>Science</i> 290(5497):1775-1779.
	10.	Chao, N.J. et al. (1993). "Granulocyte colony-stimulating factor 'mobilized' peripheral blood progenitor cells accelerate granulocyte and platelet recovery after high-dose chemotherapy," <i>Blood</i> 81(8):2031-2035.
	11.	Duncan, J.S. and Sander, J.W. (1991). "The Chalfont Seizure Severity Scale," <i>J. Neurol. Neurosurg. Psychiatry</i> . 54(10):873-876.


EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Form PTO-1449		Docket Number 286002021300	Application Number 09/997,045
INFORMATION DISCLOSURE CITATION IN AN APPLICATION (Use several sheets if necessary)		Applicant Timothy R. BRAZELTON and Helen M. BLAU	
		Filing Date November 13, 2001	Group Art Unit 1614
		Mailing Date March 4, 2002	
			
	a	Eglitis, M.A. and Mezey, E. (1997). "Hematopoietic cells differentiate into both microglia and macroglia in the brains of adult mice," <i>Proc. Natl. Acad. Sci. USA</i> 94(8):4080-4085.	
	13. j	Freshney, R.I. (1986). <u>Animal Cell Culture, a practical approach</u> , IRL Press: Oxford, pp. vii-xiii (Table of Contents).	
	14. v	Gage, F.H. et al. (1987). "Grafting genetically modified cells to the brain: possibilities for the future," <i>Neuroscience</i> 23(3):795-807.	
	15. v	Graham, D.I. and Lantos, P.L. eds. (1997). <u>Greenfield's Neuropathology, sixth edition</u> , Oxford University Press: New York pp. v-xiii (Table of Contents).	
	16. v	Gussoni, E. et al. (1999). "Dystrophin expression in the <i>mdx</i> mouse restored by stem cell transplantation," <i>Nature</i> 401(6751):390-394.	
	17. j	Harada, M. et al. (1996). "Granulocyte colony-stimulating factor-induced mobilization of peripheral blood stem cells for autologous and allogenic transplantation," <i>Cancer Chemother. Pharmacol.</i> 38(Suppl): S115-S119.	
	18. v	Harlow, E. and Lane, D. eds. (1988). <u>Antibodies: A Laboratory Manual</u> , Cold Spring Harbor Laboratory: New York pp.iii-ix (Table of Contents).	
	19. v	Howell, J.M. et al. (1991). "Natural bone marrow transplantation in cattle with Pompe's disease," <i>Neuromuscul. Disord.</i> 1(6):449-454.	
	20. j	Kennedy, D.W. and Abkowitz, J.L. (1997). "Kinetics of central nervous system microglial and macrophage engraftment: analysis using a transgenic bone marrow transplantation model," <i>Blood</i> 90(3):986-993.	
	21. v	Körbling, M. (1999). "Collection of allogeneic peripheral blood stem cells," <i>Bailliere's Clinical Haematology</i> 12(1/2):41-55.	
	22. v	Krivit, W. et al. (1999). "Bone marrow transplantation for globoid cell leukodystrophy, adrenoleukodystrophy, metachromatic leukodystrophy, and Hurler syndrome," <i>Curr. Opin. Hematol.</i> 6(6):377-82.	
	23. v	Kronenwett, R. et al. (2000). "The role of cytokines and adhesion molecules for mobilization of peripheral blood stem cells," <i>Stem Cells</i> 18:320-330.	
	24. j	McPherson, M.J. et al eds. (1995). <u>PCR 2:A Practical Approach</u> , IRL Press: Oxford, pp. ix-xvii. (Table of Contents).	
	25. j	Petersen, B.E. et al. (1999). "Bone marrow as a potential source of hepatic oval cells," <i>Science</i> 284(5417):1168-1170.	
	26. v	Pourcher, E. and Barbeau, A. (1980). "Field testing of an ataxia scoring and staging system," <i>Can. J. Neurol. Sci.</i> 7(4):339-344.	
	27. v	Sadock, B.J. and Sadock, V.A. eds. (2000). <u>Kaplan and Sadock's Comprehensive Textbook of Psychiatry, Volume 1</u> , Lippincott Williams and Wilkins: Philadelphia, pp. vii-xviii (Table of Contents).	
EXAMINER:		DATE CONSIDERED:	
EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.			

 RECEIVED
 MAR 12 2002
 PATENT & TRADEMARK OFFICE

Form PTO-1449		Docket Number 286002021300	Application Number 09/992,045
INFORMATION DISCLOSURE CITATION IN AN APPLICATION (Use several sheets if necessary)		Applicant Timothy R. BRAZELTON and Helen M. BLAU	
		Filing Date November 13, 2001	Group Art Unit 1614
		Mailing Date March 4, 2002	
	28.	Sambrook, J. et al. (1989). <u>Molecular Cloning: A Laboratory Manual, second edition</u> , Cold Spring Harbor Laboratory Press: New York, pp. xi-xxxviii. (Table of Contents).	
	29. ✓	Schere, L.J. et al. (1992). "Human Dopa decarboxylase: localization to human chromosome 7p11 and characterization of hepatic cDNAs," <i>Genomics</i> 13(2):469-471.	
	30. ✓	Tabbara, I.A. et al. (1997). "The role of granulocyte colony-stimulating factor in hematopoietic stem cell transplantation," <i>Cancer Investigation</i> 15(4):353-357.	
	31. ✓	Takahashi, K. et al. (1990). "Infantile osteopetrosis complicating neuronal ceroid lipofuscinosis," <i>Pathol. Res. Pract.</i> 186:697-706.	
	32. ✓	Wolff, J.A. et al. (1989). "Grafting fibroblasts genetically modified to produce L-dopa in a rat model of Parkinson disease," <i>Proc. Natl. Acad. Sci. U.S.A.</i> 86(22):9011-9014.	
			
EXAMINER:		DATE CONSIDERED:	
EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.			